Sensei Biotherapeutics (NASDAQ:FTH) Shares Climb 17.3% - Should You Buy?

Key Points

• Sensei Biotherapeutics shares jumped 17.3% to about $19.74, with trading volume 64% above average.
• Analyst sentiment remains broadly positive, with a consensus “Buy” rating and a $56.25 target price, despite one recent downgrade to “Sell.”
• The clinical-stage cancer immunotherapy company reported a quarterly loss of $2.84 per share, outperforming estimates, while institutional investors own 10.5% of its stock.

Sensei Biotherapeutics, Inc. (NASDAQ:FTH - Get Free Report)'s stock price was up 17.3% on Tuesday. The company traded as high as $19.69 and last traded at $19.7390. Approximately 409,958 shares traded hands during mid-day trading, an increase of 64% from the average session volume of 249,784 shares. The stock had previously closed at $16.83.

Wall Street Analyst Weigh In

FTH has been the subject of a number of research analyst reports. Wall Street Zen cut Sensei Biotherapeutics from a "hold" rating to a "sell" rating in a report on Saturday, September 26th. Oppenheimer began coverage on shares of Sensei Biotherapeutics in a report on Tuesday, July 28th. They set an "outperform" rating and a $60.00 price objective on the stock. Needham & Company LLC began coverage on shares of Sensei Biotherapeutics in a report on Friday, August 21st. They set a "buy" rating and a $56.00 price objective on the stock. JonesTrading began coverage on shares of Sensei Biotherapeutics in a research report on Tuesday, August 4th. They issued a "buy" rating and a $55.00 price objective for the company. Finally, William Blair began coverage on shares of Sensei Biotherapeutics in a research note on Friday, October 16th. They issued an "outperform" rating for the company. Three investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $56.25.

Sensei Biotherapeutics Stock Up 14.4%

The firm's 50-day moving average is $29.91. The stock has a market cap of $497.50 million, a price-to-earnings ratio of -0.14 and a beta of -0.29.

Sensei Biotherapeutics (NASDAQ:FTH - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share for the quarter, topping the consensus estimate of ($5.04) by $2.20. On average, equities research analysts anticipate that Sensei Biotherapeutics, Inc. will post -13.69 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sensei Biotherapeutics

A number of large investors have recently added to or reduced their stakes in FTH. Citadel Advisors LLC bought a new position in shares of Sensei Biotherapeutics during the 2nd quarter worth approximately $307,000. Renaissance Technologies LLC grew its position in Sensei Biotherapeutics by 178.2% in the first quarter. Renaissance Technologies LLC now owns 32,041 shares of the company's stock valued at $1,010,000 after purchasing an additional 20,525 shares in the last quarter. Bank of America Corp DE grew its position in Sensei Biotherapeutics by 10,692.5% in the first quarter. Bank of America Corp DE now owns 33,025 shares of the company's stock valued at $1,041,000 after purchasing an additional 32,719 shares in the last quarter. Stempoint Capital LP acquired a new stake in Sensei Biotherapeutics in the 1st quarter valued at $4,188,000. Finally, Alyeska Investment Group L.P. bought a new position in shares of Sensei Biotherapeutics in the 2nd quarter valued at about $3,610,000. Institutional investors own 10.50% of the company's stock.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company's research is designed to activate and direct the immune system against tumors, with an emphasis on treatments that may address immune-suppressive mechanisms in the tumor microenvironment.

Sensei's pipeline has included SNS-101, an investigational antibody targeting VISTA, an immune checkpoint believed to limit anti-tumor immune responses, and SNS-301, an investigational cancer vaccine developed using the company's ImmunoPhage platform.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.